Signifor

Drug Overview

In the complex field of Endocrinology, the management of pituitary-driven hormonal excess requires a sophisticated pharmacological approach. Signifor is a high-affinity, multi-receptor ligand classified within the Somatostatin Analog drug class. It is specifically designed as a Targeted Therapy to address the overproduction of adrenocorticotropic hormone (ACTH) at its source within the pituitary gland.

Unlike traditional therapies that may target the adrenal glands or require invasive surgical intervention, Signifor offers a biochemical solution to restore the delicate balance of the hypothalamic-pituitary-adrenal (HPA) axis. By mimicking the inhibitory actions of the natural hormone somatostatin, Signifor provides physicians with a potent tool to manage the multi-systemic ravages of chronic cortisol excess.

• Generic Name: Pasireotide diaspartate
• US Brand Names: Signifor (immediate-release), Signifor LAR (long-acting release)
• Route of Administration: Subcutaneous injection (Signifor); Intramuscular injection (Signifor LAR)
• FDA Approval Status: FDA-approved (Initial approval in December 2012 for Cushing’s disease; subsequent approval for Acromegaly in 2014)

What Is It and How Does It Work? (Mechanism of Action)

The regulation of ACTH and cortisol is governed by a series of receptors on the surface of pituitary tumor cells. Specifically, somatostatin receptors (SSTRs) act as the “off switch” for hormone secretion. There are five known subtypes of these receptors, labeled SSTR1 through SSTR5.

In Cushing’s disease, the pituitary corticotroph tumor cells predominantly express SSTR5. Traditional Somatostatin Analogs, such as octreotide, primarily bind to SSTR2, which is often under-expressed in these specific tumors. This is where Signifor represents a clinical breakthrough.

At the molecular and hormonal level, Signifor acts as a pan-somatostatin receptor agonist with a binding affinity for SSTR5 that is approximately 40 times greater than that of octreotide. When Signifor binds to the SSTR5 receptor on the corticotroph adenoma:

1. ACTH Inhibition: It triggers an intracellular signaling cascade that inhibits the synthesis and secretion of ACTH.
2. Cortisol Reduction: With lower circulating ACTH, the adrenal glands receive fewer signals to produce cortisol, leading to a significant decrease in Urinary Free Cortisol (UFC) levels.
3. Tumor Modulation: By engaging multiple receptor subtypes (SSTR1, 2, 3, and 5), it may also exert anti-proliferative effects on the tumor cells themselves, potentially leading to tumor shrinkage over long-term treatment.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Signifor (subcutaneous) is the treatment of adult patients with Cushing’s disease for whom pituitary surgery has not been curative or is not an option. It is used to normalize cortisol levels and alleviate the physical and metabolic symptoms of the disorder.

Other Approved & Off-Label Uses

The broader application of pasireotide includes:

• Acromegaly: Marketed as Signifor LAR, it is indicated for patients who are inadequately controlled by surgery or other somatostatin analogs.
• Carcinoid Syndrome (Off-label): Sometimes utilized in refractory cases of neuroendocrine tumors.
• Dumping Syndrome (Off-label): Investigated for its ability to slow gastric emptying and modulate gut hormones.

Primary Endocrinology Indications:

• Biochemical Control of Hypercortisolism: Aiming for the normalization of 24-hour Urinary Free Cortisol (UFC) to restore metabolic health.
• Symptomatic Management: Targeted reduction of “moon face,” truncal obesity, and proximal muscle weakness associated with cortisol excess.
• Hormonal Balancing: Restoring the circadian rhythm of the HPA axis by suppressing pathological ACTH “spikes.”

Dosage and Administration Protocols

Signifor requires careful titration. The immediate-release subcutaneous formulation is typically started at a lower dose to assess tolerance, particularly regarding blood glucose levels, which can be significantly impacted by this medication.

Indication	Standard Dose	Frequency
Cushing’s Disease (Initial)	0.6 mg or 0.9 mg	Twice Daily (Subcutaneous)
Cushing’s Disease (Maintenance)	0.3 mg to 0.9 mg	Twice Daily (Subcutaneous)
Acromegaly / Cushing’s (LAR)	10 mg to 40 mg	Once Every 4 Weeks (IM)

Special Population Adjustments:

• Hepatic Insufficiency: For patients with moderate hepatic impairment (Child-Pugh B), the recommended initial dose is 0.3 mg twice daily. It should be avoided in severe hepatic impairment.
• Renal Function: No specific dose adjustment is required for renal impairment, but monitoring is advised.
• Titration Schedule: Dose increases are usually considered after 2 months of therapy if UFC levels remain elevated and the drug is well-tolerated.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

The efficacy of Signifor has been rigorously established through Phase III clinical trials, most notably the B2305 study. Research updated through 2026 continues to highlight its role in achieving biochemical targets.

Biochemical Target Data

• UFC Normalization: In pivotal trials, approximately 26% of patients on the 0.9 mg dose achieved normalization of UFC without a dose reduction after 6 months.
• Mean Cortisol Reduction: Patients experienced a mean reduction in UFC of approximately 48% to 50% from baseline, often within the first two months of therapy.
• Metabolic Markers: Beyond cortisol, trials showed a mean reduction in systolic and diastolic blood pressure (approx. 5-7 mmHg) and a mean reduction in LDL cholesterol, though these were often offset by changes in glucose metabolism.
• Weight Management: Patients showed a mean weight loss of approximately 4.5 kg to 6.0 kg over 12 months, directly related to the reduction in hypercortisolism.

Research from 2024 suggests that Signifor LAR (the monthly injection) provides a more stable biochemical profile, with a 40% UFC normalization rate in patients who showed early sensitivity to the subcutaneous version.

Safety Profile and Side Effects

Black Box Warning: There is no Black Box Warning for Signifor. However, the FDA requires a specific warning regarding the risk of severe hyperglycemia (high blood sugar).

Common Side Effects (>10%)

• Gastrointestinal: Diarrhea, nausea, abdominal pain, and gallstones (cholelithiasis).
• Metabolic: Hyperglycemia and Type 2 Diabetes (occurring in up to 73% of patients).
• Systemic: Fatigue, headache, and injection site reactions.

Serious Adverse Events

• Adrenal Insufficiency: If cortisol levels drop too low, patients may experience an adrenal crisis (hypocortisolism).
• Bradycardia: A slow heart rate and potential QT prolongation on EKG.
• Hepatotoxicity: Elevation of liver enzymes (ALT/AST).

Management Strategies:

Glucose monitoring is the most critical management strategy. Physicians often initiate Metformin or GLP-1 receptor agonists proactively when starting Signifor. Patients must also be educated on “sick day” protocols to recognize the signs of low cortisol (extreme weakness, dizziness, and low blood pressure).

Research Areas

Direct Clinical Connections

Active research (2025-2026) is focusing on the drug’s interaction with Pancreatic Beta-Cell Preservation. While pasireotide inhibits insulin secretion, newer studies are exploring if co-administration with dipeptidyl peptidase-4 (DPP-4) inhibitors can mitigate this effect. There is also significant interest in the HPA axis “reset”—investigating if long-term pasireotide therapy can induce long-term remission of the pituitary adenoma.

Generalization and Advancements

The field is moving toward Novel Delivery Systems, including potential oral versions of somatostatin analogs. Furthermore, the development of Biosimilars for older analogs has paved the way for more cost-effective access to Signifor as patents evolve. Clinical trials are currently assessing “Pulse Therapy,” where Signifor is cycled to prevent receptor desensitization.

Severe Disease & Prevention

A major pillar of current research is the prevention of macrovascular complications (heart attack and stroke) by rapidly controlling the Cushingoid phenotype. By normalizing cortisol within 3-6 months, Signifor is being studied for its ability to reverse diabetic cardiomyopathy and prevent end-stage renal disease in Cushing’s patients.

Patient Management and Clinical Protocols

Pre-treatment Assessment

An endocrinologist must establish a comprehensive baseline:

• Baseline Diagnostics: 24-hour UFC, morning serum cortisol, and ACTH levels.
• Metabolic Panel: HbA1c, fasting plasma glucose, and lipid profile.
• Organ Function: Liver function tests (ALT/AST/Bilirubin) and gallbladder ultrasound to screen for pre-existing stones.
• Cardiac Screening: Baseline EKG to measure the QT interval.

Monitoring and Precautions

• Vigilance: Glucose monitoring must occur weekly for the first 3 months and monthly thereafter.
• Hormonal Escape: Monitoring for “therapeutic escape” where cortisol levels begin to rise again after initial control.
• Lifestyle: Medical Nutrition Therapy (MNT) is vital. Patients should follow a consistent carbohydrate counting plan to manage pasireotide-induced hyperglycemia.
• “Do’s and Don’ts” List:
  • DO learn to self-inject in different sites to avoid skin thickening.
  • DO carry a medical alert bracelet indicating “Cushing’s Disease/Potential Adrenal Insufficiency.”
  • DON’T stop the medication abruptly without a tapering plan from your doctor.
  • DON’T ignore symptoms of gallstones, such as sudden pain in the upper right abdomen.

Legal Disclaimer

This document is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Signifor is a potent Hormone Replacement Therapy (in its inhibitory role) and must be used only under the strict supervision of a licensed endocrinologist. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide